Director, Clinical and Translational Development
Natera- Full Time
- Senior (5 to 8 years)
The Lead, Cell Therapy Platform should possess a strong understanding of digital platform development and deployment, with experience in leading cross-functional teams and managing complex projects. Demonstrated ability to gather and translate business requirements into technical specifications is essential, along with a customer-centric mindset and experience in optimizing user experiences. Prior experience in the biotechnology or pharmaceutical industry is preferred, and a Bachelor’s degree in a related field is required.
As the Cell Therapy Platform Lead, you will serve as the business owner of Orca Bio’s digital ordering and coordination platform, driving strategy, development, and implementation to ensure it effectively supports customer workflows such as ordering, scheduling, and delivery. You will partner closely with the technical team to convey functional requirements, manage development priorities, and oversee project execution, while also overseeing the project budget and ensuring alignment with customer needs and internal processes. Furthermore, you will lead feedback-driven improvements, implement tools and training to enhance customer support and usability, and continuously monitor platform performance and customer experience to ensure seamless integration and satisfaction.
Develops and commercializes cell therapies
Orca Bio operates in the biotechnology sector, specifically focusing on cell therapies that utilize the body's own cells to treat diseases. The company works to enhance these therapies, aiming to make them safer and more effective for patients. Orca Bio's products are primarily used by healthcare providers who administer these therapies to patients as part of their treatment plans. Unlike many competitors, Orca Bio emphasizes a strong team culture and values communication with stakeholders, keeping them informed about the company's progress and developments. The goal of Orca Bio is to improve patient outcomes through advanced cell therapies, addressing conditions that currently have limited treatment options.